960539-70-2
- Product Name：Daprodustat
- Molecular Formula：C19H27N3O6
- Purity：99%
- Molecular Weight：393.44
Product Details:
CasNo： 960539-70-2
Molecular Formula： C19H27N3O6
Buy High Grade Daprodustat ,Hot Sale 960539-70-2 Cheap Price
- Molecular Formula:C19H27N3O6
- Molecular Weight:393.44
- PKA:3.44±0.10(Predicted)
- PSA：124.09000
- Density:1.359±0.06 g/cm3(Predicted)
- LogP:1.52630
Daprodustat(Cas 960539-70-2) Usage
|
Description |
Daprodustat is a medication categorized as a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It is primarily used for the treatment of anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months. |
| Function | Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, such as daprodustat, work by inhibiting the activity of prolyl hydroxylase enzymes. By doing so, they prevent the degradation of hypoxia-inducible factor (HIF), a protein that plays a crucial role in the body's response to low oxygen levels. This inhibition leads to increased production of erythropoietin, a hormone responsible for stimulating the production of red blood cells in the bone marrow, thereby promoting erythropoiesis. |
| Approval | The approval of daprodustat by regulatory agencies such as the FDA in the United States and in Japan signifies its recognition as a significant advancement in the treatment of anemia associated with CKD. With its oral administration and demonstrated efficacy, daprodustat offers a promising option for patients requiring treatment for CKD-related anemia, potentially improving their quality of life and treatment adherence. |
| Uses | Daprodustat represents an oral alternative to conventional erythropoiesis-stimulating agent (ESA) therapy, offering a convenient treatment option for CKD-related anemia. Clinical trials have demonstrated daprodustat's effectiveness in increasing and maintaining hemoglobin levels in CKD patients with anemia, comparable to traditional ESA therapies such as epoetin alfa or darbepoetin alfa. Additionally, daprodustat has shown cardiovascular safety comparable to ESA therapy. |
960539-70-2 Relevant articles
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients
Ajay K. Singh, MBBS1,2; Borut Cizman, MD3; Kevin Carroll, PhD, CStat, CSci4
, JAMA Intern Med. 2022;182(6):592-602.
In this randomized clinical trial of 312 ID patients, daprodustat was noninferior to darbepoetin alfa in treating anemia of CKD; the difference in mean hemoglobin concentration between study arms during the evaluation period was 10.5 g/dL for patients receiving daprodustat and 10.6 g/dL for patients receiving darbepoetin alfa.
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
Amy M Meadowcroft, Borut Cizman, Louis Holdstock, Nandita Biswas, Brendan M Johnson, Delyth Jones, A Kaldun Nossuli, John J Lepore, Michael Aarup, Alexander R Cobitz
, Clinical Kidney Journal, Volume 12, Issue 1, February 2019, Pages 139–148
The primary outcome was characterization of the dose–response relationship between daprodustat and hemoglobin at 4 weeks; additionally, the efficacy and safety of daprodustat were assessed over 24 weeks.
960539-70-2 Upstream products
-
2387-23-7
1,3-Dicyclohexylurea
-
35824-91-0
1,3-dicyclohexyl barbituric acid
Relevant Products
-
ApixabanCAS：503612-47-3
-
AprocitentanCAS：1103522-45-7
-
EncorafenibCAS：1269440-17-6
